Tag: company

NASHVILLE, Tenn., June 12, 2025 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the "Company”), a leading lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and entertainment experiences, announced today that it will release its second quarter 2025 earnings results after the market closes on Monday, August 4, 2025. Management will hold a conference call to discuss the quarter's results at 10 a.m. ET on Tuesday, August 5, 2025.

UAB "Atsinaujinančios energetikos investicijos" (hereinafter, the “Company”) on 11 June 2025 has finished a public offering led by FMĮ “Orion securities” during which the Company has successfully distributed 32.274 MEUR Green Bonds first series and first tranche issue at 8.0% yield, under its EUR 100 million unsecured fixed-interest note programme. The base prospectus of the programme was approved by the Bank of Lithuania on 27 May 2025. This transaction marks a continuation of the implementation of a distinctive Green Bond Programme in the Baltic market. The proceeds from the note issuance will be used to refinance existing bonds (ISIN LT0000405938).

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.20 per share on shares of its common stock for the quarter ending June 30, 2025. The dividend will be payable on July 30, 2025 to common stockholders of record as of the close of business on June 23, 2025.

ABSECON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Absecon Bancorp (the “Company”) (OTC, trading as ASCN), the bank holding company of First National Bank of Absecon, an Atlantic County New Jersey based community bank, announced today that its Board of Directors declared a regular quarterly cash dividend in the amount of $0.90 per share, payable on June 30, 2025 to shareholders of record as of June 20, 2025.

Châtillon, France, June 12, 2025

PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study’s lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial’s second active clinical site.

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities